Posted on: March 25, 2010
Aderans Research Institute Inc. (ARI) announced it acquired key
technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair regeneration company. By acquiring the scientific assets of one of its chief competitors, ARI has further solidified its position as the leading research company in the hair regeneration industry.
“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field, an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”
The purchase includes assets related to the ICX-TRC product that had been a research focus for Regenerative Medicine Assets Limited. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness and female diffuse alopecia.
The deal comes as ARI is extending its Phase 2 clinical study of cell-based hair regeneration, in which it recently treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should substantially augment our efforts to create a viable cell-based solution for hair loss.”
“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this field is a significant step forward in our efforts to pioneer a regenerative process that can deliver enhanced hair
growth to millions of people around the world.” |
|
|
|
